Breaking News

Public sector programs in some low- and middle-income countries will obtain access to Hologic's Panther system through a single, all-inclusive pricing structure.

The company said it plans to use the financing to increase adoption of its MammaPrint BluePrint next-generation sequencing-based test kit for breast cancer.

The firm will manufacture its Logix Smart mycobacteria tuberculosis assay at its ISO-certified facility in Utah but will not seek FDA approval at this time, it said.

The firm will use the proceeds for working capital, but said it may also acquire or invest in complementary technologies or businesses.

The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.

The STRIDES program aims to establish industry partnerships to provide NIH researchers access to cost-effective computational infrastructure, tools, and services.

The funding from the Mark Foundation for Cancer Research will support an initiative to investigate cancer genomics in ethnically diverse populations.

The agency is seeking one or two sequencing centers for the Gabriella Miller Kids First Research Program.

The firm will work with the FDA to speed the approval process for its liquid biopsy assay, Elio, which analyzes SNVs, amplifications, rearrangements, and MSI.

The company posted Q2 revenues of $596.2 million, up from $558.3 million in Q2 2017, short of the average Wall Street estimate of $598 million.

The firm said that its average revenue per clinical genetic test decreased by almost 4 percent to $318, primarily due to changes in Medicare reimbursement and regulation.

Built by two of the creators of Nextflow, former Techstars company Lifebit makes scaleable genomic analysis technology that runs in the cloud.

When researchers sequenced some 800 global Staphylococcus aureus isolates, they saw signs of previous jumps from humans to domestic animals and beyond.

Palmetto proposes to cover the assay for prostate cancer patients who are at very low and low risk of negative outcomes with active surveillance by NCCN guidelines.

The lab will make Lucence's non-invasive cancer tests available to patients in the region, but financial and other terms were not disclosed.

The firm beat analysts' consensus estimates on both the top and bottom lines, and it raised its 2018 annual revenue guidance.

The company hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.

A polygenic prediction score based on those SNPs accounts for more than 11 percent of the variance seen between individuals in educational attainment.

A new deep neural network approach used common variants in non-human primate genomes to distinguish between benign variants and those involved in human disease.

The scientists collected fecal samples from more than 9,000 pigs and chickens to find in excess of 400 antimicrobial resistance genes, which varied by country.

The system is for high-throughput testing in central labs and the firm plans additional assays for infectious and sexually transmitted diseases.

HLI claims that upon his termination in May, Venter took a company-owned laptop and is using HLI trade secrets to build a competing business at JCVI.

The company will work with researchers at UCSD's Moores Cancer Center on two studies of patients with breast, lung, and colon cancers.

As part of the deal, Waters has also placed a Synapt G2-Si mass spec instrument at Purdue University to help advance research applications for DESI.

The final LCD, which expands Medicare coverage of the firm's ConfirmMDx test to all providers, becomes effective on Sept. 3.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.